Autopsy report · NCT02683941
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
Cause of deathOther
“National Comprehensive Cancer Network \& European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.”
Life of this trial
- Registered 1 year 6 months before it started.
- Ran for about 3 years before it stopped.
- 77 participants enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Ipsen
- Sponsor type
- Industry
- Conditions
- Neuroendocrine Tumors in Lung
- Interventions
- Lanreotide (Autogel formulation); Placebo; Best Supportive Care
- Participants
- 77
- Sites
- 57
- Countries
- Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.